Invasive fungal diseases most often occur in the blood or spread to the eyes, liver, spleen, bones, heart valves, central nervous system, etc. through secondary spread. Causative pathogens include Candida, Aspergillus, and Cryptococcus. lts increased incidence is related to the increased susceptibility of immunocompromised patients to IFl, especially in patients with AIDS, blood diseases, malignancies, organ transplants, or burns. Invasive fungi can affect various tissues and systems throughout the body, the most common of which is respiratory tract infection.

Advantages of Dynamiker Fungal Detection Kit

5G

+Pro

GM

G

GXM

CA-IgG

Mn

PCR Assay

AF-IgE

AF-IgG

Innovative

Based on this detection scheme for fungal diseases, multi-item testing of specimens from the same patient can accurately detect fungal species, make up for the limitations of single-item testing, and provide a reference for the rational use of antifungal drugs. After adding PCR tests, it has now been upgraded to"5G+ Pro".

Authoritative Recognition

The product performance is supported by many authoritative literature at home and abroad, and related research results are published in professional journals. At the same time, in the report on the detection and treatment of fungal infections issued by WHO, with reference to many academic articles published by Dynamier, combined with the excellent performance of fungal detection reagents in clinical trials, 6 fungal detection reagents were recommended.

Types of Fungal Detection Kit

Pan-fungal Screening

Pan-fungal screening can effectively screen a variety of fungal infections, including Candida, Aspergillus, etc. (excluding Cryptococcus and Zygomycetes), by detecting the fungal cell wall component (1-3)-B-D-glucan(BDG), providing a key basis for the early detection and accurate diagnosis and treatment of fungal infections.



Dynamiker Fungus (1-3)-β-D-Glucan Assay



Dynamiker Fungus (1-3)-β-D-Glucan Assay (ELISA)



QuicG Fungus (1-3)-β-D-Glucan Lateral Flow Assay



Dynamiker Fungus (1-3)-β-D-Glucan Assay (POCT CLIA)

Aspergillosis

Serological testing is a core tool for the diagnosis of aspergillosis. Galactomannan antigen testing is used for early warning of acute invasive Aspergillus infection, and antibody testing is used to diagnose chronic diseases such as chronic pulmonary aspergillosis (CPA) or allergic acute invasive aspergillosis (ABPA).



Dynamiker Aspergillus Galactomannan Assay



Dynamiker Aspergillus Fumigatus IgG Assay



QuicGM Aspergillus Galactomannan Ag Lateral Flow Assay



QuicIgG Aspergillus IgG Ab Lateral Flow Assay



QuicIgE Aspergillus IgE Ab Lateral Flow Assay



Dynamiker Aspergillus Galactomannan Assay (POCT CLIA)



Dynamiker Antigen Aspergillus fumigatus IgG Assay (POCT CLIA)



MycoMDx Aspergillus PCR Assay



MycoMDx PCR Assay for Detection of 3 Fungal Pathogens

Candidiasis

Serological testing for candida infections primarily enables rapid diagnosis by analyzing fungal antigens or antibodies in blood and is particularly suitable for invasive candida infections (such as candidemia and deep organ infections).



Dynamiker Candida Mannan Assay



Dynamiker Candida Albicans IgG Assay



QuicIgG Candida IgG Lateral Flow Assay



QuicMn Candida Mannan Ag Lateral Flow Assay



Dynamiker Candida Mannan Assay (POCT CLIA)



Dynamiker Candida albicans IgG Assay (POCT CLIA)



MycoMDx Candida PCR Assay



MycoMDx Candida Auris PCR Kit

Cryptococcosis

The serological test for cryptococcosis is based on the detection of the capsular polysaccharide antigen (GXM) and is suitable for screening for meningitis, disseminated infection, and high-risk populations.



Dynamiker Cryptococcal Antigen Lateral Flow Assay(LFA)



QuicGXM Cryptococcus Neoformans Ag Lateral Flow Assay



Dynamiker Cryptococcus neoformans Antigen Assay (POCT CLIA)

Mucormycosis

Identifying Mucorales fungi at the genetic level provides an important basis for quickly identifying the pathogen of infection. It is especially suitable for patients with acute invasive Mucorosis who are immunocompromised (such as diabetic ketoacidosis and bone marrow transplant patients).



MycoMDx Mucor PCR Assay

Pneumocystis Jiroveci

In clinical applications, this technology has key value in the diagnosis of Pneumocystis jiroveci pneumonia (PCP) in immunocompromised populations (such as HIV-infected patients, cancer chemotherapy patients, and organ transplant recipients).



MycoMDx Pneumocystis Jirovecii (PJP) PCR Assay

Talaromyces Marneffei

lt is suitable for early screening of patients suspected of having T.marneffei infection but with negative traditional culture results, as well as immunocompromised populations (such as HIV-infected patients and lymphoma patients).



MycoMDx Talaromyces Marneffei PCR Assay

Fungal Detection Instrument

The compatible instruments for different methodological reagents are displayed here.



Dry Fluorescence Immunoassay Analyzer



Automated CLIA System

PCR Series

The MycoMDx PCR Series offers advanced molecular diagnostic solutions for rapid and accurate detection of clinically significant fungal pathogens.

If you want to know more kinds of aspergillus antibodies test kits and monkeypox rt pcr kit, please visit our website.

We can also offer kinds of candida igg blood test and cryptococcus neoformans antigen test kits for sale. If you are interested, please leave us a message.

Dynamiker was founded in 2014 as a specialist in the diagnosis of invasive fungal diseases. It is dedicated to the R&D, production and global sales of innovative in vitro diagnostic products for invasive fungal disease (IFD) and other pathogenic microorganisms. Dynamiker biotechnology actively cooperates with GAFFI to promote the establishment of international reference laboratories and industry standards, participates in industry-university research and international project cooperation, and has a strategic cooperation with Pfizer China to jointly promote the accurate use of clinical antifungal drugs.

Our fungal detection instruments are designed to deliver rapid, accurate, and reliable diagnostic results for clinical laboratories and healthcare institutions. Featuring advanced technologies such as dry fluorescence immunoassay test and automated chemiluminescent enzyme immunoassay (CLEIA), these systems ensure high sensitivity, streamlined workflows, and consistent performance.

Types of Fungal Detection Instruments

Dry Fluorescence Immunoassay Analyzer

Automated CLIA System

Dynamiker was founded in 2014 as a specialist in the diagnosis of invasive fungal diseases. It is dedicated to the R&D, production and global sales of innovative in vitro diagnostic products for invasive fungal disease (IFD) and other pathogenic microorganisms. Dynamiker actively cooperates with GAFFI to promote the establishment of international reference laboratories and industry standards, participates in industry-university research and international project cooperation, and has a strategic cooperation with Pfizer China to jointly promote the accurate use of clinical antifungal drugs.

Dynamiker Fungus 1 3 BD Glucan Assay

It's used for pan-fungal detection. (1-3)-β-D-glucan is the major cell wall component of most fungi such as Candida, Aspergillus in blood, Fusarium, etc. By spectrophotometric quantitative detection of (1-3)-β-D-glucan in human sample, this assay provides a diagnostic reference for invasive fungal diseases.

Specification

Principle

The pre-treated sera are added to the main reagent containing Factor G. Factor G is activated by (1-3)-β-D-glucan and the activated Factor G converts the proclotting enzyme to the clotting enzyme.

The clotting enzyme hydrolyses the substrate(Boc-leu-Gly-Arg-PNA) to release PNA.

The absorbance is measured kinetically at 405 nm.

The concentration of (1-3)-B-D-glucan is interpreted from a standard curve.

Adaptation Platform

The BDG Assay is working on a microplate reader with kinetic reading at 405nm and temperature control at 37C.

Recommended microplate readers are Tecan Sunrise or BioTek ELX808iu, with incubator and kinetic reading at 405nm.

Clinical Performance

White PL, et al: An evaluation of the performance of the Dynamiker®Fungus (1-3)-B-D-Glucan Assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and Pneumocystis pneumonia. Med Mycol. 2017 Nov 1;55(8) : 843-850

Shabaan AE, et al: Role of serum 1,303-d-glucan assay in early diagnosis of invasive fungal infections in a neonatal intensive care unit. J Pediatr (Rio J). 2017.

Now price of fungus test kit is reasonable, anything you need, please contact us.

If you want to know more kinds of aspergillus galactomannan blood test, aspergillus serum test and beta glucan blood test kits, please visit our website.

Dynamiker biotechnology was founded in 2014 as a specialist in the diagnosis of invasive fungal diseases. It is dedicated to the R&D, production and global sales of innovative in vitro diagnostic products for invasive fungal disease (IFD) and other pathogenic microorganisms. Dynamiker actively cooperates with GAFFI to promote the establishment of international reference laboratories and industry standards, participates in industry-university research and international project cooperation, and has a strategic cooperation with Pfizer China to jointly promote the accurate use of clinical antifungal drugs.

Dynamiker Cryptococcal Antigen Lateral Flow Assay(LFA)

The 2022 WHO guidelines show that cryptococcal meningitis is one of the most common opportunistic infections among HIV-infected people, especially in patients with advanced AIDS.

It is used for the detection of capsular polysaccharide antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii) in human ssamples. This cryptococcus lateral flow assay can be used as a screening diagnosis for cryptococcal meningitis.

Specification

Guideline

WHO guidelines for the Diagnosis, Prevention, and Management of Cryptococcal Disease in Hiv-Infected Adults, Adolescents, and Children, 2018

Screening for cryptococcal antigen followed by preemptive antifungal therapy among cryptococcal antigen-positive people to prevent the development of invasive cryptococcal disease is recommended before initiating or reinitiating ART for adults and adolescents living with HIV who have a CD4 cell count<100 cells/mm3 (strong recommendation; moderate-certainty evidence) and may be considered at a higher CD4 cell count threshold of <200 cells/mm3 (conditional recommendation; moderate-certainty evidence).

Clinical Performance

Evaluation of the new Dynamiker cryptococcal antigen Lateral Flow Assay (LFA) in comparison with IMMY LFA and Meridian latex agglutination test. Poster no 1197.

Now price of aspergillus lateral flow device is reasonable, anything you needm okease contact us.

CSF cryptococcal antigen test can be performed rapidly with the lateral flow assay method, which enables on-site detection without requiring complex laboratory equipment. This test is recommended for routine screening among people living with HIV who have a CD4 cell count below 100 cells/mm3, helping to identify cryptococcal infection early before the onset of clinical symptoms. For commercial inquiries about customized csf cryptococcal antigen testing reagents or to obtain the latest product quotation, please contact our sales team via the contact information listed on our official website.

Aspergillus galactomannan antigen positive results often indicate the presence of invasive aspergillosis, a life-threatening fungal infection that commonly occurs in immunocompromised patients including organ transplant recipients, patients receiving long-term immunosuppressive therapy and patients with hematological malignancies. To further confirm the diagnosis, clinicians usually need to combine the test results with imaging findings such as chest CT scans and clinical symptoms of the patient, to avoid misdiagnosis caused by possible false positive results. If you need technical support for the interpretation of test results or supporting documents for clinical research applications, you can contact our technical support team at XX.